DCT

1:26-cv-00140

Abraxis Bioscience LLC v. Qilu Pharmaceutical Hainan Co Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: Abraxis BioScience, LLC v. Qilu Pharmaceutical (Hainan) Co., Ltd., 1:26-cv-00140, D.N.J., 01/08/2026
  • Venue Allegations: Venue is asserted based on Defendant Qilu being a foreign company, which may be sued in any judicial district under 28 U.S.C. § 1391(c)(3).
  • Core Dispute: Plaintiff alleges that Defendant's proposed generic drug product, for which it has submitted an Abbreviated New Drug Application (ANDA), will infringe seven U.S. patents covering the branded drug Abraxane®.
  • Technical Context: The lawsuit concerns nanoparticle-based drug delivery systems for chemotherapeutic agents, specifically paclitaxel, which are designed to improve solubility and reduce side effects associated with conventional formulations.
  • Key Procedural History: The complaint notes that Defendant Qilu has previously been sued in the District of New Jersey and has not challenged personal jurisdiction, and has also asserted counterclaims in the district, suggesting a history of availing itself of the jurisdiction. The complaint also references prior litigation involving some of the same patents against different parties.

Case Timeline

Date Event
2005-02-18 Earliest Priority Date for all Patents-in-Suit
2010-07-20 U.S. Patent No. 7,758,891 Issues
2011-10-11 U.S. Patent No. 8,034,375 Issues
2012-09-18 U.S. Patent No. 8,268,348 Issues
2015-08-11 U.S. Patent No. 9,101,543 Issues
2016-07-19 U.S. Patent No. 9,393,318 Issues
2016-12-06 U.S. Patent No. 9,511,046 Issues
2017-03-21 U.S. Patent No. 9,597,409 Issues
2025-11-26 Alleged earliest date Qilu sent Paragraph IV notice letter
2026-01-08 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,758,891

  • Patent Identification: U.S. Patent No. 7758891, "Combinations and Modes of Administration of Therapeutic Agents and Combination Therapy," issued July 20, 2010.

The Invention Explained

  • Problem Addressed: The patent describes the poor target specificity and severe side effects of conventional chemotherapy agents, which are often a major dose-limiting toxicity (DLT) '891 Patent, col. 1:56-2:14 Specifically for the drug paclitaxel, its poor aqueous solubility necessitates the use of formulation vehicles like Cremophor®, which itself can cause severe hypersensitivity reactions and may compromise the drug's efficacy '891 Patent, col. 5:21-49
  • The Patented Solution: The invention provides methods for treating cancer using a taxane, such as paclitaxel, formulated in a nanoparticle composition with a carrier protein like albumin '891 Patent, abstract This formulation avoids the need for Cremophor®, potentially improving safety and allowing for higher dosing '891 Patent, col. 5:49-53 The patent also describes administering the nanoparticle taxane in combination with other therapies or in a "metronomic" dosing regime (low, frequent doses) to target tumor vasculature '891 Patent, col. 5:7-20
  • Technical Importance: This approach represented an effort to improve the therapeutic index of a potent but difficult-to-deliver class of chemotherapy drugs by leveraging biocompatible nanoparticles for delivery.

Key Claims at a Glance

  • The complaint does not identify specific claims but alleges infringement of "one or more" of the patent's claims Compl. ¶30 Claim 1 is a representative independent claim.
    • Independent Claim 1: A method of treating a proliferative disease in an individual comprising:
      • administering to the individual a composition comprising nanoparticles comprising a taxane and a carrier protein,
      • wherein the nanoparticles in the composition have an average diameter of no greater than about 200 nm,
      • and wherein the weight ratio of the carrier protein to the taxane in the nanoparticle composition is about 18:1 or less;
      • and administering to the individual an effective amount of an antimetabolite agent.

U.S. Patent No. 8,034,375

  • Patent Identification: U.S. Patent No. 8034375, "Combinations and Modes of Administration of Therapeutic Agents and Combination Therapy," issued October 11, 2011.

The Invention Explained

  • Problem Addressed: As with the '891 Patent, this patent addresses the challenge of treating proliferative diseases like cancer, which often resist conventional drug and radiation therapy '375 Patent, col. 1:26-34 It highlights the severe side effects and dose-limiting toxicities of traditional chemotherapy, which are caused by poor target specificity and the use of toxic solubilizing agents '375 Patent, col. 1:56-2:27
  • The Patented Solution: The patent claims methods of treating cancer by administering a nanoparticle composition of a taxane (like paclitaxel) and a carrier protein (like albumin) in combination with a second therapy, which can be another chemotherapeutic agent, radiation, or surgery '375 Patent, abstract '375 Patent, col. 7:1-9 This combination approach aims to overcome the shortcomings of single-modality treatments '375 Patent, col. 2:35-39
  • Technical Importance: This patent expanded the proprietary space around the nanoparticle taxane formulation by explicitly claiming its use in combination with a wide range of other standard-of-care cancer treatments.

Key Claims at a Glance

  • The complaint does not identify specific claims but alleges infringement of "one or more" of the patent's claims Compl. ¶39 Claim 1 is a representative independent claim.
    • Independent Claim 1: A method of treating non-small cell lung cancer (NSCLC) in a human individual comprising administering to the individual:
      • a) an effective amount of a composition comprising nanoparticles comprising paclitaxel coated with albumin, and
      • b) an effective amount of a platinum-based agent,
      • wherein the platinum-based agent is cisplatin or carboplatin, and
      • wherein the nanoparticle composition is free of cremophor.

Multi-Patent Capsules

  • U.S. Patent No. 8268348: "Combinations and Modes of Administration of Therapeutic Agents and Combination Therapy," issued September 18, 2012.

    • Technology Synopsis: This patent is a continuation of the patent family and continues to claim methods of treating various cancers, including NSCLC and pancreatic cancer, by administering a nanoparticle taxane composition in combination with a platinum-based agent like carboplatin. The invention focuses on specific administration schedules, such as weekly administration of the nanoparticle taxane with the platinum agent administered every three weeks '348 Patent, abstract '348 Patent, col. 1:17-2:19
    • Asserted Claims: "one or more claims" Compl. ¶48
    • Accused Features: The proposed manufacture and use of Qilu's ANDA Product, a generic version of Abraxane® Compl. ¶48

  • U.S. Patent No. 9101543: "Combinations and Modes of Administration of Therapeutic Agents and Combination Therapy," issued August 11, 2015.

    • Technology Synopsis: This patent further builds on the core invention, claiming methods for treating metastatic pancreatic cancer. It specifies a combination therapy of a nanoparticle paclitaxel-albumin composition and gemcitabine, detailing specific dosages and administration schedules, such as a weekly regimen for three out of four weeks '543 Patent, abstract
    • Asserted Claims: "one or more claims" Compl. ¶57
    • Accused Features: The proposed manufacture and use of Qilu's ANDA Product Compl. ¶57

  • U.S. Patent No. 9393318: "Methods of Treating Cancer," issued July 19, 2016.

    • Technology Synopsis: This patent claims methods of treating non-small cell lung cancer (NSCLC) by administering a nanoparticle paclitaxel-albumin composition and carboplatin. The claims are directed at treatment based on the patient having specific characteristics, such as squamous cellular carcinoma, or being at least 70 years old '318 Patent, abstract '318 Patent, claim 1
    • Asserted Claims: "one or more claims" Compl. ¶66
    • Accused Features: The proposed manufacture and use of Qilu's ANDA Product Compl. ¶66

  • U.S. Patent No. 9511046: "Methods of Treating Pancreatic Cancer," issued December 6, 2016.

    • Technology Synopsis: This patent focuses specifically on treating metastatic pancreatic cancer. It claims methods comprising the administration of a nanoparticle paclitaxel-albumin composition and gemcitabine, with claims directed to patients having specific clinical characteristics, such as the presence of liver metastasis or a high number of metastatic sites '046 Patent, abstract
    • Asserted Claims: "one or more claims" Compl. ¶75
    • Accused Features: The proposed manufacture and use of Qilu's ANDA Product Compl. ¶75

  • U.S. Patent No. 9597409: "Methods of Treating Cancer," issued March 21, 2017.

    • Technology Synopsis: This patent covers methods for treating prostate cancer. It claims a method of administering a nanoparticle docetaxel-albumin composition in combination with a steroid, such as prednisone. This represents a variation on the core technology by using a different taxane (docetaxel) and targeting a different cancer type '409 Patent, abstract
    • Asserted Claims: "one or more claims" Compl. ¶84
    • Accused Features: The proposed manufacture and use of Qilu's ANDA Product Compl. ¶84

III. The Accused Instrumentality

  • Product Identification: "Qilu's ANDA Product," a proposed generic version of Abraxane® (paclitaxel protein-bound particles for injectable suspension) Compl. ¶1 The ANDA number is 220144 Compl. ¶1
  • Functionality and Market Context: The complaint alleges that Qilu's ANDA Product is a generic drug intended for the same uses as Abraxane®, which is an FDA-approved medicine for treating metastatic breast cancer, non-small cell lung cancer, and pancreatic cancer Compl. ¶11 The product is a formulation of paclitaxel bound to protein, designed for injection Compl. ¶1 Abraxis alleges that the claims of the Patents-in-Suit cover the FDA-approved methods of use for Abraxane® Compl. ¶11 and that the patents are listed in the FDA's Orange Book with respect to Abraxane® Compl. ¶12 The filing of ANDA No. 220144 with a Paragraph IV certification is the statutory act of infringement giving rise to this suit (Compl. ¶¶25; Compl. ¶27).

IV. Analysis of Infringement Allegations

The complaint does not provide specific infringement allegations in the form of a claim chart or detailed technical comparison. Instead, it makes general allegations that Qilu's submission of its ANDA to obtain approval to manufacture and sell its generic product constitutes infringement of the Patents-in-Suit under 35 U.S.C. § 271(e)(2)(A) Compl. ¶30 Compl. ¶39 Compl. ¶48 Compl. ¶57 Compl. ¶66 Compl. ¶75 Compl. ¶84 The infringement theory is that Qilu's proposed product, as a generic version of Abraxane®, will have the same active ingredient, dosage form, and methods of use, which are alleged to be covered by the claims of the patents-in-suit Compl. ¶11 Compl. ¶13 The complaint does not provide sufficient detail for a claim chart analysis.

  • Identified Points of Contention:
    • Claim Scope: The patents-in-suit cover not only the composition of matter but also specific methods of administration, including dosing regimens, schedules, and use in combination with other agents for various cancer types. A potential point of contention is whether the label for Qilu's ANDA product will instruct physicians to perform all of the specific steps recited in the asserted method claims.
    • Technical Equivalence: A central question will be whether Qilu's ANDA product meets every limitation of the asserted claims. This may involve disputes over the characteristics of the nanoparticles (e.g., average diameter, carrier protein ratio) and whether Qilu's formulation is truly bioequivalent in a way that satisfies the patent claim limitations, not just the FDA's regulatory standards.
    • Validity: While not an infringement issue, the primary point of contention in Hatch-Waxman litigation is typically the defendant's challenge to the validity of the asserted patents on grounds such as obviousness or lack of enablement. Qilu's Paragraph IV certification implies it will argue the patents are invalid, not infringed, or unenforceable Compl. ¶27

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

Analysis based on the representative independent claims from the '891 and '375 patents.

Term 1: "nanoparticles comprising a taxane and a carrier protein" ('891 Patent, Claim 1)

  • Context and Importance: This term defines the fundamental nature of the drug delivery vehicle. The construction of this term is critical because it determines what specific formulations fall within the patent's scope. Qilu may argue its formulation process or resulting particle characteristics differ in a way that places its product outside this definition.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification describes various carrier proteins, including "proteins normally found in blood or plasma," such as albumin, immunoglobulin, and lipoproteins, and various taxanes '891 Patent, col. 47:56-48:6 This suggests the term is not limited to only paclitaxel and human serum albumin.
    • Evidence for a Narrower Interpretation: The specification repeatedly refers to the preferred embodiment of paclitaxel and albumin, and the commercial product Abraxane™ is specifically an albumin-bound paclitaxel formulation '891 Patent, col. 5:53-54 A defendant might argue that the scope should be limited to the embodiments that are actually enabled and described in detail, particularly those involving albumin.

Term 2: "average diameter of no greater than about 200 nm" ('891 Patent, Claim 1)

  • Context and Importance: This size limitation is a key technical parameter of the claimed nanoparticles. Infringement will depend on whether Qilu's product has a particle size distribution that meets this requirement. Practitioners may focus on this term because size can affect the biological behavior and efficacy of nanoparticles, making it a potentially dispositive limitation.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The term "about" suggests some flexibility in the 200 nm upper limit. The specification also discusses nanoparticles with diameters up to 1000 nm, although it notes a preference for smaller sizes '891 Patent, col. 47:33-38 This could support an argument that the 200 nm limit is not a strict, absolute cutoff.
    • Evidence for a Narrower Interpretation: The claim explicitly recites "about 200 nm," and the detailed description emphasizes the advantages of smaller particles, for example, for sterile-filtration and potentially for biological transport mechanisms '891 Patent, col. 47:38-40 A defendant could argue this creates a clear demarcation that its product does not meet.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement under 35 U.S.C. § 271(b), stating that upon FDA approval, Qilu will "intentionally encourage acts of direct infringement" with knowledge of the patents Compl. ¶33 This is likely based on the assertion that Qilu's product labeling will instruct medical professionals and patients to use the generic drug in accordance with the patented methods Compl. ¶13 Contributory infringement under 35 U.S.C. § 271(c) is also alleged, based on the product being "especially adapted for a use that infringes" and having "no substantial non-infringing use" Compl. ¶34
  • Willful Infringement: The complaint does not use the word "willful" but alleges that the case is "exceptional" and seeks attorneys' fees under 35 U.S.C. § 285 Compl. ¶37 This allegation is predicated on Qilu's knowledge of the patents, which is established at the latest by its receipt of the complaint and is alleged to exist pre-suit via the ANDA filing and Paragraph IV notice letter Compl. ¶28

VII. Analyst's Conclusion: Key Questions for the Case

  1. Claim Construction and Scope: A central issue will be the construction of key claim terms, such as "nanoparticles comprising... a carrier protein" and the specific size limitation "average diameter of no greater than about 200 nm." The outcome of the case may turn on whether Qilu's ANDA product, as characterized in its application, falls within the scope of these terms as construed by the court.

  2. Infringement of Method Claims: The patents-in-suit include numerous method-of-use claims tied to specific diseases (e.g., NSCLC, pancreatic cancer) and administration protocols (e.g., combination with carboplatin). A key question will be whether the proposed label for Qilu's generic product will induce infringement by instructing practitioners to perform every step of these claimed methods, creating a direct link between the label's instructions and the patented therapeutic regimens.

  3. Patent Validity: As is standard in Hatch-Waxman litigation, a dispositive question for the court will be the validity of the asserted claims. Qilu will likely challenge the patents-in-suit on grounds of obviousness, arguing that the claimed combinations of the nanoparticle formulation with other known cancer therapies or specific dosing regimens would have been obvious to a person of ordinary skill in the art at the time of the invention.

Loading Complaint